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Immunoproteasomes are alternative forms of protea-
somes that have an enhanced ability to generate
antigenic peptides. Recently, Seifert and colleagues
reported surprising observations concerning the
functions of immunoproteasomes and cellular
responses to interferon-g: (1) that immunoprotea-
somes degrade ubiquitinated proteins faster than
the constitutive proteasomes, (2) that polyubiquitin
conjugates accumulate after interferon-g treatment
but then are preferentially degraded by immunopro-
teasomes, and (3) that immunoproteasome defi-
ciency causes the formation of inclusions and more
severe experimental autoimmune encephalomyelitis
(EAE). In contrast, we find that polyubiquitin conju-
gates do not transiently accumulate following IFNg-
treatment and that immunoproteasomes do not
prevent the formation of intracellular inclusions or
protect against EAE. Furthermore, purified 26S con-
stitutive and immunoproteasomes bind ubiquitin
conjugates similarly and degrade them at similar
rates. We conclude that, although immunoprotea-
somes can increase the generation of peptides
appropriate for MHC class I presentation, they do
not degrade ubiquitinated proteins more efficiently
than constitutive particles.
INTRODUCTION
The presentation of intracellular peptides by MHC class I mole-
cules at the cell surface is essential for immune surveillance,
as well as for the detection of intracellular pathogens bymaraud-
ing cytotoxic T cells (Groettrup et al., 2010). Protein breakdown
by proteasomes generates the great majority of these peptides
that are loaded onto the MHC class I complex (Rock and Gold-1184 Cell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc.berg, 1999; Rock et al., 1994). The constitutive 26S proteasome
is a 2.5 megadalton complex composed of the 20S catalytic
chamber, which contains the b subunits that catalyze peptide
hydrolysis (b1, b2, and b5), and the 19S regulatory particle, which
binds the polyubiquitinated substrates. The 19S base contains
six ATPase subunits that catalyze protein unfolding, gate
opening into the 20S core, and translocation into the central
chamber of the 20S particle (Finley, 2009; Peth et al., 2010; Smith
et al., 2011). After exposure of most cells to interferon-g (IFNg) or
tumor necrosis factor (TNF)-a, special forms of the proteasome
termed immunoproteasomes are expressed, in which the three
catalytic subunits of the 20S are replaced by homologous
subunits, b1i /LMP2, b2i/LMP10 (MECL1), and b5i/LMP7. In
addition to this induction in inflammatory states, these alterna-
tive forms are actually found normally in immune tissues. Due
to their distinct peptidase sites, they cleave proteins in a distinct
manner from constitutive particles and generate more peptides
capable of binding to MHC class I molecules, thereby serving
an important role in antigen presentation (Gaczynska et al.,
1993; Kincaid et al., 2012; Rock and Goldberg, 1999).
The immunoproteasome preferentially cleaves proteins after
hydrophobic residues and less after acidic residues (Aki et al.,
1994; Driscoll et al., 1993; Gaczynska et al., 1993, 1994), and
these peptides with hydrophobic C termini are preferentially
transported by TAP into the endoplasmic reticulum and
loaded onto class I molecules. In vivo studies confirm that this
change in the peptide repertoire presented at the cell surface
is important for enhancing cytotoxic T cell responses (Basler
et al., 2006; Fehling et al., 1994; Kincaid et al., 2012; Van Kaer
et al., 1994).
20S immunoproteasomes exist in cells either as free particles,
in association with the 19S regulator, (forming 26S immunopro-
teasomes), as well as in ‘‘hybrid 26S’’ with PA28ab and the 19S
regulator. Although the 20S immunoproteasome and the 20S
constitutive proteasome have distinct cleavage site preferences,
they degrade nonubiquitinated proteins at similar rates (Cascio
et al., 2001), as do the two forms of the 26S proteasome.
However, Seifert et al. (2010) recently reported evidence for
additional intriguing roles of immunoproteasomes in the rapid
breakdown of ubiquitinated proteins following cytokine expo-
sure. These observations, if validated, would have important
implications for understanding proteasomal mechanisms gener-
ally and the process of antigen presentation. They reported that
IFNg treatment caused a transient accumulation in cells of poly-
ubiquitin conjugates, which they suggested was due to ubiquiti-
nation of newly synthesized proteins. Seifert et al. (2010)
concluded that the accumulation of polyubiquitin conjugates
results from a transient decrease in proteasome activity, while
the cells are forming mature immunoproteasomes. In addition,
they reported that immunoproteasomes are more efficient than
constitutive particles in degrading polyubiquitinated proteins
and are essential to remove damaged proteins in inflammatory
states in mice, because they could efficiently digest misfolded
proteins that form aggresome-like inclusions.
Such properties of immunoproteasomes would imply that this
species of proteasome has a special capacity for eliminating
ubiquitinated proteins, especially damaged proteins, as accu-
mulate in multiple disease states and are often not efficiently
degraded by the constitutive 26S particles. However, these
proposed special functions for immunoproteasomes, which
were further elaborated in the accompanying editorial (van
Deventer and Neefjes, 2010), raises a number of fundamental
questions that are difficult to resolve with our present under-
standing of proteasome function. In particular, it is unclear how
would changes in the active site specificities of the core 20S
particle alter its capacity to bind and degrade ubiquitinated
proteins, which are functions of the 19S regulatory particles.
Because of their major implications for understanding pro-
teasome mechanisms and inflammatory responses, our two
laboratories have independently re-examined several of the
key observations reported by Seifert et al. (2010), using both
similar and alternative rigorous approaches. Our findings seri-
ously challenge several of their key observations and the result-
ing models, as we find (1) that 26S immunoproteasomes have
a similar capacity to bind and degrade polyubiquitinated
proteins, as do constitutive proteasomes. This result supports
the widely accepted view that the 19S regulatory complex (not
the 20S core particle) is critical in determining their rates of
degradation and (2) that in models of murine inflammation immu-
noproteasome deficiency has no effect on the formation of
intracellular ubiquitin-containing inclusions or the in vivo mani-
festations of experimental autoimmune encephalomyelitis.
RESULTS
IFNg Does Not Cause an Accumulation of Polyubiquitin
Conjugates during Induction of Immunoproteasomes
To determine the influence of IFNg stimulation on the cellular
content of polyubiquitin conjugates, we treated the BALB/c-
derived fibroblast cell line, B8, and freshly prepared mouse
embryonal fibroblasts (MEFs) of C57BL/6 mice with IFNg
(200 U/ml). At the indicated time points, aliquots were taken,
lysed in the same manner as used by Seifert et al. (2010), and
analyzed by western blotting with antibodies against polyubiqui-
tin and GAPDH (as a loading control). Although one of us had
previously observed an increase in polyubiquitin conjugates inIFNg-treated HeLa cells, in these experiments with B8 cells, in
contrast to the data in Seifert et al. (2010), no significant increase
in high molecular weight ubiquitin conjugates was detected in
either cell line during the 48 hr after IFNg treatment (Figures 1A
and 1B). In particular, we did not observe any transient increase
in ubiquitin conjugates as was reported by Seifert et al. (2010) in
cell line B8, 4–12 hr after IFNg addition. To confirm that the cells
were responding to IFNg, we measured the induction of the im-
munoproteasome subunit LMP7 (Gaczynska et al., 1993; Rock
and Goldberg, 1999), which typically increases following inter-
feron exposure. By 6 hr exposure to IFNg, there was an elevated
level of the functional (fully processed) LMP7 (23 kDa), which
results from proteolytic processing of the 30 kD LMP7 precursor
during the assembly of immunoproteasomes. Because this
induction of immunoproteasomes occurred without a reduction
in the amounts of polyubiquitin conjugates, there was no
experimental basis for the suggestion (Seifert et al., 2010) that
these particles have a special capability to degrade ubiquitin
conjugates.
In these experiments, cells were disrupted by use of a nonionic
detergent, which may extract both soluble polyubiquitin conju-
gates and ubiquitin containing protein aggregates. We therefore
used a more stringent method to isolate only these soluble poly-
ubiquitinated proteins that might be degraded by the 26S.
Following the IFNg treatment, the MEFs were lysed by sonica-
tion, and the soluble fraction isolated by 100,0003 g centrifuga-
tion (Figures S1A and S1B available online). Again, no significant
change in the levels of polyubiquitin conjugates was detected
after IFNg stimulation (Figures S1A and S1B). Thus, we could
find no basis for the conclusion that polyubiquitin conjugates
transiently increase after IFNg treatment.
To further explore if IFNg stimulation could be seen to cause
an accumulation of polyubiquitinated proteins, these experi-
ments were repeated using a different cell line and in another
laboratory. HeLa cells were treated with IFNg (100 U/ml), and
the levels of high molecular weight polyubiquitin conjugates
measured following cell disruption by sonication and extraction
of the soluble fraction (Figure 1C) or after lysis with nonionic
detergent (Figures S1C and S1D). These HeLa cells had re-
sponded to the IFNg because immunoproteasome subunits
and other components of the MHC class I presentation pathway,
which typically increase following IFNg exposure, were all clearly
induced. Twelve hours after the IFNg addition, LMP2 and LMP7
subunits of the immunoproteasome were induced, as well as
PA28ab and ER-associated peptidase 1 (ERAP1), which trims
longer proteasome products to eight to ten residue-peptides
for efficient loading onto the MHC class I complex (Chang
et al., 2005; Saric et al., 2002) (Figure 1D). Furthermore, flow
cytometry analysis of surface MHC class I expression showed
that there was a marked increase of class I molecules at the
plasma membrane at 48 hr, indicating a normal IFNg response
in these cells (Figure 1E). Interestingly, in these cells, the total
content of 26S and 20S particles, as measured by the 19S
component, Rpn1, and the 20S a-subunit levels, were not
altered (Figure 1C). Despite this clear induction of the IFNg-
responsive genes, there was, no reproducible change in levels
of polyubiquitin conjugates (Figures 1C and S1C). Thus despite
trying different lysis protocols and different cell lines, in theseCell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc. 1185
Figure 1. IFNg Does Not Cause an Accumulation of Polyubiquitinated Proteins during the Induction of immunoproteasomes and Other
Components of the MHC Class I Presentation Pathway
(A and B) Western blot analysis and densitometric evaluation of polyubiquitin conjugates in mouse fibroblasts after IFNg treatment. Lysates from the murine
fibroblast cell line B8 (A) and embryonal fibroblasts of C57BL/6 mice (B) were analyzed for their content of ubiquitinated proteins by western blotting after
exposure to IFNg for the indicated times (A and B, bottom). GAPDH served as loading control. The amount of LMP7 increased, confirming the expected response
to IFNg stimulation. Graphical presentation of the means ± SEM of densitometric evaluation of the immunoblots (A and B, top) showed no significant accu-
mulation of polyubiquitin conjugates after IFNg stimulation (Student’s t test).
(legend continued on next page)
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experiments we were not able to reproduce the previously re-
ported accumulation of polyubiquitin conjugates upon immuno-
proteasome induction.
Seifert et al. (2010) also reported that the ubiquitin conjugating
enzyme, Ube2L6 (also known as UbcH8), is induced following
IFNg treatment and suggested that this E2 is required for
the accumulation of polyubiquitin conjugates. One concern
regarding this conclusion is that it is now well established that
Ube2L6, although able to facilitate protein ubiquitination,
primarily functions in protein modification by ligation of the ubiq-
uitin-like protein, ISG15 (Zhao et al., 2004). ISG15 is known to be
induced by type I interferons IFNa and b rather than type II inter-
ferons (IFNg) (Zhao et al., 2005). Therefore, we tested whether
ISG15 levels and protein conjugates are also increased in the
HeLa cells following IFNg exposure. Surprisingly, we found
that monomeric ISG15 was induced with IFNg, although we
could not detect ISG15 conjugates (Figure 1D). It is currently
unclear why ISG15 increases in response to IFNg, but the mono-
meric form may have an antiviral function (Skaug and Chen,
2010). However, it is noteworthy that Seifert et al. (2010) found
that the E3 for ISG15, Herc5, was also induced, together with
Ube2L6, strongly suggesting an increased capacity for ISG15
ligation to proteins.
Proteasome Activity Does Not Transiently Decrease
in Response to IFNg
Although the total levels of ubiquitin conjugates did not change,
it remained possible that proteasomal activity had increased in
response to IFNg. To examine this possibility, HeLa cells were
treated with IFNg for up to 48 hr, and lysates isolated in the
usual manner. The total proteasomal peptidase activities in
the HeLa extracts were measured by assaying cleavage of
specific substrates of the chymotrypsin-like site, Suc-LLVY-
AMC and Suc-GGL-AMC, and of the caspase-like site, Ac-
nLPnLD-AMC. To ensure that their hydrolysis was only due to
proteasomes, the lysates were treated with the specific protea-
some inhibitor, Bortezomib (1 mM), and the Bortezomib-insensi-
tive activity subtracted from the total peptidase activity. The
proteasome’s trypsin-like activity cannot be assayed in crude
extracts due to the high nonproteasomal activity against its
standard substrates (Kisselev and Goldberg, 2005). By 12 hr
after IFNg addition, there was an increase in the proteasome’s
chymotrypsin-like activity and a decrease in its caspase-like
activity (Figures 2A–2C), which coincided with the appearance
of the immunoproteasome subunits (Figure 1D). These studies
thus confirm the changes in peptidase activity previously re-
ported upon induction of immunoproteasomes (Aki et al.,
1994; Driscoll et al., 1993; Gaczynska et al., 1993, 1994)
(Figures S1E–S1G). Importantly, we did not observe any tran-
sient decrease in proteasomal peptide-hydrolysis, as reported
(Seifert et al., 2010).(C–E) Treatment of HeLa cells with IFNg does not lead to a transient accumulation
IFNg for the indicated times. The cells were lysed by sonication and centrifugated
subunits (C), and proteins known to be involved in the IFNg response (D) were an
expression. A proportion of the HeLa cells (2 3 105) that were treated with or wit
MHC class I antibody (W6/32), and the levels of cell surface class I molecules w
See also Figure S1.To further confirm that proteasome content did not decrease
in response to IFNg, we analyzed the proteasome composition
in the total cell lysate. HeLa cells were treated with IFNg and
lysed in the usual manner. Native PAGE was used to fractionate
the different proteasome complexes, and we measured by
western blotting, the 19S regulator subunit Rpt1 and a-subunits
of the constitutive 20S proteasome, as well as proteasome
activity using in-gel Suc-LLVY-AMC hydrolysis. In accord with
our previous findings (Figure 1), there was no significant
decrease in proteasome content or activity (Figure 2D). Instead,
the levels of doubly and singly capped 26S, as well as free 20S
proteasomes remained constant following IFNg treatment.
Western blot analysis with an anti-LMP2 antibody confirmed
that the catalytic subunits of the immunoproteasomes were first
incorporated into mature 26S proteasomes by 12 hr, which coin-
cided exactly with the first observed change in proteasomal
peptidase activity in the lysates (Figures 2A–2C). Moreover,
by 48 hr, both the presence of LMP2 and the changes in pepti-
dase activity were more pronounced. Therefore, although immu-
noproteasomes were clearly generated, there was no evident
change in overall proteasome content and no decrease in
proteasome capacity. These findings and the lack of changes
in ubiquitin conjugate levels also do not support the conclusion
that 26S immunoproteasomes are more efficient than constitu-
tive particles in degrading polyubiquitinated proteins (seebelow).
Purified Immuno- and Constitutive 26S Proteasomes
Degrade Ubiquitin Conjugates Similarly
To test this conclusion more directly, we purified 26S immuno-
and constitutive proteasomes and compared their abilities to
bind and degrade polyubiquitinated substrates. Prior studies
showed that skeletal muscles contain only constitutive protea-
somes, whereas spleens largely contain immunoproteasomes
(Cascio et al., 2001; Van Kaer et al., 1994). Therefore, constitu-
tive 26S particles were affinity-purified from muscles of CD1
mice and the immunoproteasomes from their spleens as
described by Besche et al. (2009). To ensure that the total pro-
teasome content was the same for each type, we analyzed the
compositions of the purified proteasomes by SDS- and native
PAGE. The ratios of the doubly to singly capped 26S species
were comparable (Figures S2A–S2C), and as expected, the
characteristic immunoproteasome subunits were present only
in the particles from the spleens (Figure S2C). Also, the immuno-
proteasomes had approximately 2-fold greater chymotrypsin
and trypsin-like activities, but a 2-fold lower caspase-like activity
(Figures S2D–S2F).
Because Seifert et al. (2010) had reported a greater capacity
of the immunoproteasomes to degrade ubiquitinated substrates,
we compared the rates of degradation by the constitutive
and immunoproteasome species of a homogeneous polyubi-
quitinated substrate, ubiquitinated dihydrofolate reductaseof polyubiquitin conjugates. HeLa cells were treated with or without 100 U/ml
at 100,0003 g for 1 hr. The levels of the ubiquitin conjugates (C), proteasome
alyzed by western blotting. (E) IFNg treatment increased surface MHC class I
hout IFNg for 48 hr (C) were incubated with a FITC conjugated conformational
ere measured by flow cytometry.
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Figure 2. Proteasome Activity Does Not Transiently Decrease in Response to IFNg
(A–C) Following treatment with IFNg, the chymotrypsin-like activity of the 26S proteasome increased progressively, whereas the caspase-like activity decreased.
HeLa cells were treated with or without 100 U/ml IFNg for the indicated times. The proteasomal peptidase activity was then measured in the lysates using Suc-
LLVY-AMC and Suc-GGL-AMC for the chymotrypsin-like activity, and Ac-nLPnLD-AMC for the caspase-like activity. The lysates were also treated with 1 mM
Bortezomib/Velcade to determine the Bortezomib-resistant (nonproteasomal) activity, which was subtracted from the total activity at each time point to measure
only the proteasomal activity. All values are means of three separate experiments ± SEM. *p < 0.05.
(D) Native PAGE analysis of the lysates from cells treated with IFNg in (A)–(C). Lysate protein (25 mg) was separated using 3%–8% Tris-acetate gels containing
1 mMATP and 5mMMgCl2. In-gel proteasome activity was measured by incubating the gels in a Tris buffer containing 1 mMATP, 5 mMMgCl2, and 50 mMSuc-
LLVY-AMC at 37C for 30 min (D, upper-left). The activity of the 20S proteasomes was visualized by adding 0.02% SDS for 45 min (D, lower-left). Proteasome
complexes were visualized by western blotting for the 19S regulator (Rpt1), 20S proteasomes (a subunits), and immunoproteasome subunit LMP2 (D, right
panels). The 26S preparations contain both doubly (19S-20S-19S) and singly (19S-20S) capped species and there was no significant change in the levels of these
complexes following IFNg treatment.(Ub5DHFR). This substrate contains four lysines linked in a K48
chain to a ubiquitin on the N terminus of DHFR and encodes
a protein kinase A (PKA) phosphorylation site near its C terminus.
The ubiquitinated DHFR could therefore be radiolabeled using
32P-ATP, allowing the precise monitoring of its degradation by
measuring the generation of TCA-soluble peptide fragments
(Figures 3A–3C) (Lam et al., 2005). Degradation of this ubiquiti-
nated DHFR was blocked by proteasome inhibitors or metho-
trexate, which prevent the degradation of the DHFR both by
pure 26S (Peth et al., 2009) and in cells (Johnston et al., 1995).
The purified 26S proteasomes from the mouse muscles and
spleens were incubated with the radiolabeled Ub5DHFR and1188 Cell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc.ATP at 37C for up to 30 min. The 32P-Ub5DHFR was degraded
by the isolated constitutive and immunoproteasomes at virtually
the same rate (Figure 3A). To compare their degradative capac-
ities more precisely, we incubated them with increasing concen-
trations of nonradiolabeled Ub5DHFR added and a constant
amount of the 32P-Ub5DHFR, The Michaelis-Menten analysis
showed no significant difference in their Km (140 nM spleen,
180 nM muscle) or Vmax (5 nM/min spleen, 5 nM/min muscle)
for Ub5DHFR degradation by the constitutive or immunoprotea-
somes (Figure 3C).
To examine whether these proteasome species might bind
ubiquitin conjugates more efficiently, we used a resin-bound
Figure 3. Immunoproteasomes and Constitutive 26S Proteasomes Degrade Polyubiquitinated Conjugates at Similar Rates
Constitutive 26S proteasomes were isolated from muscles and immunoproteasomes from spleens of CD1 mice using the Ubl method (Besche et al., 2009). The
subunit content of the different proteasome species, and their peptidase activity are shown in Figure S2.
(A–C) The 26S constitutive proteasome and 26S immunoproteasome degrade Ub5DHFR at identical rates. The proteasome substrate,
32P-Ub5DHFR (B), was
incubated at 37C for 30 min with the pure proteasomes isolated from muscles and spleens of CD1 mice. Degradation of the 32P-Ub5DHFR to acid-soluble
peptides was measured after precipitation of the samples with TCA (A). To calculate the Km and Vmax values, the
32P-Ub5DHFR was diluted with increasing
concentrations of unlabeled Ub5DHFR (C). All values are means of three independent experiments ± SEM. NS, not significant.
(D) 26S constitutive and immunoproteasomes bind ubiquitin conjugates similarly. The pure 26S proteasomes were incubated with resin-bound ubiquitinated
E6AP (E6APUbn) at 4
C, washed, and the proteasomes bound to the conjugates were measured (Peth et al., 2010).
(E) Ubiquitinated conjugates stimulate gate-opening similarly in the 26S constitutive and immunoproteasome. The 26S proteasomeswere incubatedwith E6AP or
E6APUbn, 1mMATP, and 5mMMgCl2 at 37
C. Gate-opening wasmeasured by the increase in peptide hydrolysis using Suc-GGL-AMC (Peth et al., 2009, 2010).
See also Figure S2.polyubiquitinated protein as an affinity ligand (Peth et al., 2010).
Lysine-48 polyubiquitin conjugates were formed by incubating
the ubiquitin ligase, E6AP, (bound to a GST resin), with E1, E2,
ubiquitin, and ATP (Kim et al., 2007; Peth et al., 2009). These
conjugates were then incubated with the pure muscle or spleen
26S proteasomes at 4C, and the amounts bound were
measured (Peth et al., 2010). As shown in Figure 3D, there was
no difference in the abilities of the constitutive and the im-
muno-26S-proteasomes to bind to polyubiquitin chains.Once a polyubiquitin chain binds to the 19S component of the
proteasome, they stimulate peptide hydrolysis by binding to the
deubiquitinating enzyme, USP14, and by enhancing opening of
the gated channel into the 20S particle (Peth et al., 2009). We
therefore measured the ability of ubiquitin conjugates to activate
peptide hydrolysis (Peth et al., 2009) in both forms of the
26S proteasomes. When pure 26S proteasomes and immuno-
proteasomes were incubated with E6AP or polyubiquitinated
E6AP, the ubiquitin conjugates increased peptide hydrolysisCell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc. 1189
about 2-fold in both the constitutive and immuno- 26S particles
(Figure 3E). Thus, no evidence could be found by any of these
approaches for the claim by Seifert et al. (2010) that immunopro-
teasomes are more efficient in degrading ubiquitinated proteins,
and thus, no evidence that immunoproteasomes alter substrate
processing by the 19S complex.
LMP7 Deficiency Does Not Affect Formation of
Inclusions or Polyubiquitin Conjugates in Mouse
Embryonic Fibroblasts
Under stressful conditions wheremisfolded proteins accumulate
in cells, such as upon treatment with proteasome inhibitors,
all cells form inclusion-like structures (termed aggresomes or
aggresome-like-induced structures [ALIS]) that contain polyubi-
quitinated proteins (Szeto et al., 2006). Seifert et al. (2010) re-
ported that the formation of such inclusions are induced by
IFNg due to a transient decrease in proteasome activity during
the shift from 26S constitutive to immunoproteasomes. Because
we found no evidence of such a decrease in proteasome activity
following IFNg exposure, we tested whether, in fact, inclusions
are formed differently in mouse embryonal fibroblast (MEF) cells
generated from wild-type and LMP7/ mice. MEF cells from
C57BL/6 wild-type and LMP7/mice were grown on coverslips
and treatedwith IFNg (200 U/ml). Formation of ubiquitin-contain-
ing inclusions was measured by confocal microscopy of large
numbers of images. As reported by Seifert et al. (2010), we could
also detect inclusion formation after IFNg treatment in both wild-
type and LMP7/ MEFs (Figure 4A). However, in contrast to
their data, we found that the number of aggregates per cell
increased to the same extent in LMP7-deficient and wild-type
MEFs (Figure 4B). This increase in inclusions is presumably
due to accumulation of aberrant proteins through de novo
production or damage. In any case, because the loss of LMP7
did not enhance inclusion formation, the constitutive and immu-
noproteasomes seem to have similar capacities in vivo to elimi-
nate such ubiquitinated proteins, in accord with the findings on
pure proteasomes.
Furthermore, when we analyzed the levels of polyubiquitin
conjugates in MEFs from these wild-type and LMP7/ mice
by western blotting, in contrast to the findings by Seifert et al.
(2010), we again observed no transient accumulation of ubiquiti-
nated proteins in the wild-type cells after addition of IFNg, which
did induce LMP7 (Figure 4D). At first sight, it may seem contra-
dictory that the number of inclusions that contain ubiquitin conju-
gates increases in MEFs after IFNg treatment, even though the
amount of polyubiquitinated proteins remains unchanged.
However, as noted by Seifert et al. (2010), the nonionic deter-
gents NP-40 or Triton X-100 were used for lysis and will not solu-
bilize these aggregates. In addition, there was no difference in
the total amount of polyubiquitin conjugates in MEFs from
wild-type and LMP7/ mice 24 and 48 hr after IFNg treatment
(Figure 4C) as confirmed by quantitative densitometric analysis
(Figure 4E).
LMP7-Deficient Mice Are Not More Susceptible to
Experimental Autoimmune Encephalomyelitis
Because our findings do not support an increased capacity of
immunoproteasomes to degrade polyubiquitinated proteins,1190 Cell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc.we also investigated the proposed special role of immunopro-
teasomes in enhancing the cell’s ability to combat systemic
inflammatory conditions. We therefore examined the in vivo
effects of LMP7 deficiency using the same model of multiple
sclerosis used by Seifert et al. (2010), experimental autoimmune
encephalomyelitis (EAE). LMP7/ and C57BL/6 control mice
were immunized with MOG35–55 peptide to induce EAE. The
disease scores of the mice were recorded in a blinded manner
for 21 days. No significant difference in disease scores was
observed between LMP7/ and wild-type mice (Figure 5), in
clear contrast to the results reported by Seifert et al. (2010) but
consistent with the study by Frausto et al. (2007), who found
no effect of LMP2 deficiency on the course of EAE. Thus, the im-
munoproteasome does not have a protective effect against the
development of EAE-induced inflammation.
DISCUSSION
It is now well established that the presence of immunoprotea-
somes is important for efficient MHC class I presentation and
cytokine production (Groettrup et al., 2010; Kincaid et al.,
2012), which accounts for their presence in white blood cells
and induction during inflammation. Furthermore, the altered
peptidase activity of the immuno-b-subunits can nicely account
for their ability to generate an altered antigen repertoire. The
findings of Seifert et al. (2010) indicated that in addition, immuno-
proteasomes have an enhanced capacity to degrade polyubiqui-
tinated conjugates, which would mean that somehow the active
sites in the central chamber of the 20S core particle alter the
ability of the 19S to bind and process ubiquitinated proteins.
However, by several distinct approaches, we failed to observe
any such differences using both cellular and biochemical assays
on extracts or pure 26S particles. Although IFNg treatment did
increase the amount of ubiquitin-containing inclusions in the
cells, as Seifert et al. (2010) reported, there was no difference
in their levels in immunoproteasome-deficient MEFs. Further-
more, using the same lysis conditions as Seifert et al. (2010), or
our more stringent method of isolating the soluble fraction, the
total levels of polyubiquitin conjugates in cell lines (HeLa) or
primary cells (MEFs) remained unchanged after IFNg exposure.
How or why polyubiquitinated proteins accumulate in inclusions
following IFNg treatment is not clear and both are interesting
questions for further study. These inclusions presumably contain
damaged polyubiquitinated proteins, resembling aggresomes,
perhaps due to free-radical damage to cell proteins as Seifert
et al. (2010) suggest. However, their accumulation clearly is
not due to changes in total cell proteasome content, which
remains constant. Ubiquitin-containing inclusions are also
observed following oxidative stress and can contain both short-
and long-lived proteins (Kopito, 2000; Szeto et al., 2006). These
inclusions can be cleared by both proteasomal and autophagy
pathways (Szeto et al., 2006), but immunoproteasomes do not
appear to have any distinctive role in this process.
Our experiments provide further evidence that the changes in
proteasome peptidase activity following IFNg exposure reflects
the formation of the immunoproteasomes and their altered
cleavage specificities, and is not due to any decrease or increase
in total proteasome capacity. Measurements of a single
Figure 4. LMP7 Deficiency Does Not Affect Formation of Ubiquitin-Containing Inclusions and Total Soluble Ubiquitin Conjugates in
MEF Cells
(A) Formation of ubiquitin containing inclusions (ALISs) was visualized with a LSM510 confocal laser-scanning microscope (Carl Zeiss) after staining MEF cells
with the ubiquitin-specific mAb FK2 (green). In MEFs from LMP7/ and C57BL/6 wild-type mice (BL6WT), ubiquitin was detectable in ALIS after IFNg exposure
for the indicated times. MEFs from LMP7 deficient and wild-type mice showed similar kinetics of ALIS formation. Scale bar, 20 mm.
(B) Statistical evaluation of the number of ALIS per cell was performed for three independent experiments ± SEM (p value = 0.54 for 48 hr data; N > 210 cells). The
images were analyzed with ImageJ software.
(C)Western blot analysis of ubiquitin conjugates inMEFs from LMP7/ andC57BL/6 wild-typemice at different times after exposure to IFNg; a-tubulin served as
loading control. One representative experiment out of three independent experiments with similar outcomes is shown.
(D) The induction of LMP7 by 200U/ml IFNg stimulation was confirmed by immunoblot analysis; a-tubulin served as loading control.
(E) Graph showing the ubiquitin levels determined by densitometric analyses of four different western blots of the kind shown in (C); shown are the mean values ±
SD (p value = 0.61 for 48 hr data points) obtained after normalization to a-tubulin and relative to the value for C57BL/6wild-typemice before IFN-g stimulation (BL6
WT 0 hr) that was set to 100%. No statistically significant enhancement of ubiquitin conjugates after IFNg treatment and also no significant difference between
MEFs from WT and LMP7/ mice was found.peptidase activity to proteasome function can be misleading.
As Seifert et al. (2010) measured only the chymotrypsin-like
activity in the lysates (that increases selectively with incorpora-tion of the immune-b-subunits), it is not possible to conclude that
proteasomes are ‘‘more active’’ following IFNg treatment. Any
such analysis must also take into account the ‘‘caspase-like’’Cell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc. 1191
Figure 5. LMP7-Deficient Mice Are Not More Susceptible to Exper-
imental Autoimmune Encephalomyelitis Than Wild-Type Mice
C57BL/6 wild-type and LMP7/ mice were immunized with MOG35-55
peptide. Mice were daily monitored for clinical symptoms of experimental
autoimmune encephalomyelitis (EAE). Symptoms were scored as: 0, no
detectable signs of EAE; 0.5, distal limp tail; 1, complete limp tail; 1.5, limp tail
and hind limb weakness; 2, unilateral partial hind limb paralysis; 2.5, bilateral
partial hind limb paralysis; 3, complete bilateral hind limb paralysis; 3.5,
complete hind limb paralysis and unilateral forelimb paralysis; 4, total paralysis
of fore and hind limbs; 5, death. (y axis) is plotted versus time post-
immunization (x axis). Data represent means ± SEM of six mice. The experi-
ments were performed three times, yielding similar results.site, which in immunoproteasomes is less active against
acidic substrates and cleaves more after large hydrophobic
residues (Rock and Goldberg, 1999). In fact, we found no
decrease in proteasome content after IFNg exposure, and
instead, there is the steady maturation and increase in 26S
immunoproteasomes.
The present studies used several newly developed quantita-
tive assays for 26S function including the accurate kinetic
measurement of breakdown of a ubiquitinated protein, Ub5-
DHFR, which until recently had not been possible, as well as
ubiquitin conjugate binding to the 26S proteasome and the
ability of ubiquitinated proteins to activate peptide hydrolysis
by the 26S proteasome. In addition, we also measured the
levels of 20S proteasomes, and the singly and doubly capped
26S particles, which is important for rigorous comparisons of
the degradation of ubiquitinated proteins by the immuno-
and constitutive 26S. Our demonstration that these particles
bind and degrade ubiquitinated proteins at similar rates is
consistent with prior findings that the 20S and 26S immuno-
proteasomes degrade denatured ovalbumin at the same rates
as the corresponding constitutive particles (Cascio et al.,
2001). Furthermore, immunoproteasome deficient mice, which
lack the LMP2, 7, and 10 catalytic subunits, show clear
defects in presenting MHC class I epitopes, but no difference
in the total levels of polyubiquitin conjugates measured by
immunoblot (Kincaid et al., 2012). As polyubiquitinated
proteins bind initially to the 19S ubiquitin receptors Rpn10
and Rpn13 subunits, which do not differ between the immuno-
and constitutive 26S, it is not surprising that they degrade
ubiquitin conjugates similarly. In addition, the recent structural
analysis of the binding surfaces for the 19S regulator both of
the immuno- and constitutive 20S proteasome shows high1192 Cell 152, 1184–1194, February 28, 2013 ª2013 Elsevier Inc.similarity, such that the gating mechanisms for substrate entry
are unlikely to differ (Huber et al., 2012). In summary, the
complimentary efforts of our two labs yielded no evidence
that ubiquitinated proteins are degraded faster by the im-
muno-26S proteasomes.
The roles of the other proteasome regulators following IFNg
exposure (e.g., PA28ab) on protein degradation is less clear.
Although PA28 is induced, its precise functions in antigen
presentation and perhaps in other proteasomal processes (Pick-
ering et al., 2010) are still unclear. Hybrid proteasomes (19S-
20S-PA28) have been shown to generate a different peptide
repertoire compared to the constitutive 26S proteasome, but
show no increase in the rate of protein breakdown (Cascio
et al., 2002). PA28ab has also been suggested to increase the
ubiquitin-independent degradation of oxidatively damaged
proteins, although biochemical evidence on PA28’s specific
role and mechanism are still lacking (Pickering et al., 2010).
Further studies are required to clarify how PA28ab promotes
immune surveillance in response to IFNg and degradation of
specific types of damaged proteins, and whether as suggested
(Seifert et al., 2010; van Deventer and Neefjes, 2010), these
seemingly distinct roles are linked.
The results of Seifert et al. (2010) have been used to propose
a model of immunoproteasome function in which newly tran-
scribed proteins are damaged by IFNg-induced free radicals,
leading to increased proteasomal degradation and MHC class
I presentation, as well as the formation of ubiquitin-containing
inclusions (van Deventer and Neefjes, 2010). We have not found
any evidence that immunoproteasomes have a greater capacity
for degradation of ubiquitinated proteins, andwe have also failed
to confirm other aspects of this proposed model. There is pres-
ently no evidence that MHC class I peptides are derived from
newly synthesized, oxidatively damaged proteins. Although
IFNg has been reported to induce oxidative damage in mouse
models of inflammation, such as EAE (Espejo et al., 2002), the
mechanism for this oxidative stress is not clear and could be
through macrophage activation, neutrophil recruitment, or other
complex mechanisms. Induction of iNOS by IFNg results in
protein nitration rather than protein carbonylation, and the oxida-
tive damage that Seifert et al. (2010) documented was with the
Oxyblot method, which detects carbonyl groups on proteins
and not protein nitration.
Finally, these observations show that ISG15, a ubiquitin-like
protein that is induced by IFN a and b, is also significantly
induced by IFNg. Although we did not identify ISGylated
proteins, the induction of the E2 for ISGylation (Ube2L6) and
the E3 (Herc5) by IFNg strongly suggests that some cell proteins
are likely to be modified by formation of ISG15 conjugates.
Indeed, ISGylation of newly transcribed proteins can inhibit virus
production (Durfee et al., 2010), but no evidence has been
obtained that ISG15 is promoting proteasomal degradation
and/or MHC class I restricted presentation. In summary,
although immunoproteasomes have a clear role in the generation
of MHC class I peptides and in cytokine induction (Muchamuel
et al., 2009), they do not preferentially degrade polyubiquitinated
proteins, remove ubiquitin-containing inclusions, or significantly
alter the progression or severity of experimental autoimmune
encephalomyelitis.
EXPERIMENTAL PROCEDURES
Cell Lines, Tissue Culture, and Mice
HeLa cells were cultured in DMEM medium under standard conditions. The
murine fibroblast cell line B8 (Groettrup et al., 1995) and mouse embryonic
fibroblasts (MEF), prepared from C57BL/6 mice and LMP7/ mice (Fehling
et al., 1994), were cultivated under standard conditions and kept in IMDM or
DMEM-medium. Mice were kept in a specific pathogen-free facility and
used at 6–10 weeks of age. Animal experiments were approved by the review
board of Regierungspra¨sidium Freiburg.
Western Blotting and IFNg Stimulation
HeLa cells were stimulated with 100 U/ml IFNg for the indicated time points.
The cells were then lysed by sonication in 25 mM HEPES pH 7.4, 1 mM
ATP, 1 mM DTT, 5 mM MgCl2, and 10% glycerol. Protein concentration of
the lysates were determined using the Bradford reagent (Pierce) and equal
amounts of protein were separated by SDS PAGE and analyzed by western
blotting. The murine B8 cells and MEFs were stimulated with 200 U/ml murine
recombinant IFNg (Peprotech) for the indicated time points and lysed either in
20 mM TRIS-HCl, pH 7.5, 10 mM EDTA, 100 mM NaCl, 1% NP40, 10 mM
MG-132, 5 mM NEM, and Complete Protease Inhibitor Cocktail (Roche) (Fig-
ure 1B), or in 10 mM Tris, 150 mM NaCl, 1% Triton X-100 (Figure 4C) and the
amount of protein was determinedwith a Pierce BCA protein assay kit (Thermo
scientific). Western blot analysis was performed in the usual manner.
Purification of 26S Proteasomes from Mouse Tissues
26S particles were purified from muscles and spleens of CD1 mice by the
Ubl-affinity method in the presence of 150 mM NaCl (Besche et al., 2009).
Protein content was measured by Bradford assay and the levels of pure
proteasomes in the different tissues were normalized to the levels of the
constitutive subunits, Rpt1, Rpt5, and the 20S a subunits, determined by
western blot densitometry evaluation (ImageJ quantification).
Measurements of Proteasome Activity
Suc-LLVY-AMC, Suc-GGL-AMC, Suc-LLR-AMC, and Ac-nLPnLD-AMC were
purchased from Bachem. Cell lysates (5 mg) were incubated with the peptides
in a buffer containing 50 mM Tris pH 7.4 with 40 mM KCl, 5 mM MgCl2, 1 mM
ATP, and 1 mM DTT. Kinetic fluorescence was measured in triplicate in a
96-well format (Molecular Devices). The fluorescence was normalized to
AMC levels by first generating a standard curve for AMC fluorescence. The
lysates were also treated with 1 mM Bortezomib to inhibit specifically the
proteasome’s peptidase activity. The low amount of Bortezomib-resistant
activity in the lysate was then subtracted from the total peptidase activity, so
that only the proteasome-specific fluorescence was measured. The peptidase
activity of the pure proteasomes was measured, as described using 2 nM of
pure proteasomes.
Proteasomal degradation of a polyubiquitinated protein was measured
using Ub5DHFR as the substrate. Ub5DHFR (a kind gift of Millenium Pharma-
ceuticals) was radiolabeled as described previously with some modifications
(Lam et al., 2005). Ub5DHFR (10 mg) was incubated with 20 U PKA, 50 mCi
ATP[32P], 1 mg BSA at 37C for 15 min in a buffer containing 20 mM Tris pH
7.5, 100 mM NaCl, 10 mM MgCl2, and 1 mM DTT. The nonlabeled Ub5DHFR
was removed by passing the reaction through a BioRad MicroSpin column.
Isolated mammalian proteasomes (2 nM) were then incubated with 30 nM of
the 32P-Ub5DHFR for up to 30 min in 50 mM Tris pH 7.4, 5 mM MgCl2,
2 mM ATP, 1 mM DTT, and 0.0 2mg/BSA (total reaction volume 30 ml). Twenty
microliters of the reaction was then added to 20 ml of ice cold BSA (10 mg/ml),
and the proteins precipitated by adding 34 ml of ice cold 40% TCA. The
samples were incubated on ice for 10 min and centrifuged at 13,000 rpm for
10 min. Supernatants (20 ml) were added to 4 ml of scintillation fluid, and the
acid soluble counts measured.
Immunocytochemistry
MEFs from C57BL/6 wild-type or LMP7/ mice were grown on coverslips in
24-well plates and treated with 200 U/ml IFNg (Peprotech) for the indicated
times. Cells were fixed for 20 min with 4% paraformaldehyde and permeabi-
lized with 0.2% Triton X-100 for 10 min at room temperature and stainedwith an anti-ubiquitin monoclonal antibody FK2 (ENZO, dilution 1:500). Cells
were first labeled with primary antibodies, followed by washing and incubation
with the respective Alexa Fluor-labeled secondary antibody (F(ab)2) (dilution
1:400, Invitrogen). All antibodies were diluted in 0.2% gelatin. All incubations
were carried out for 1 hr at room temperature. Images were analyzed with
an LSM510 confocal laser-scanning microscope (Carl Zeiss) using a 633
plan-apochromat, oil-immersion objective (NA = 1.4). Pictures were analyzed
with ImageJ software. To quantify the ‘‘ALIS,’’ random fields of at least 70 cells
were stained for ubiquitin with the FK2 mAb, and the number of ALIS/cell was
assessed by counting extranuclear, ubiquitin positive structures larger than
0.5 mm2. The number of ALIS per cell was calculated by dividing the total
area of FK2 fluorescence of all ALIS per cell by the minimum ALIS-size of
0.5 mm2. Statistical analysis was performed for three independent experiments
(N > 210 cells).
Induction of EAE
C57BL/6 mice were immunized subcutaneously in the lateral abdomen with
200 mg MOG35–55 peptide in CFA, and pertussis toxin (200 ng) in PBS was
administered on day 0 (intraperitoneally [i.p.]) and day 2 (i.p.). The synthetic
peptide MOG35–55 (MEVGWYRSPFSRVVHLYRNGK) was obtained from
GenScript (Piscataway, NJ). Disease symptoms were scored as indicated in
the legend to Figure 5.
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